Breast Reduction Epidemiology and Complications in Nonbinary, Transgender, and Cisgender Adults (Q30162)

No description defined

Breast Reduction Epidemiology and Complications in Nonbinary, Transgender, and Cisgender Adults.

Language	Label	Description	Also known as
English	Breast Reduction Epidemiology and Complications in Nonbinary, Transgender, and Cisgender Adults	No description defined	Breast Reduction Epidemiology and Complications in Nonbinary, Transgender, and Cisgender Adults.

Statements

1 reference

Breast Reduction Epidemiology and Complications in Nonbinary, Transgender, and Cisgender Adults. (English)

1 reference

stated in

PubMed

abstract

Research in gender-affirming chest surgery has primarily compared cisgender versus transgender and gender-diverse (TGD) people, without specifically addressing nonbinary people. (English)

source label

INTRODUCTION (English)

subsection NLM category

1

2024

1 reference

This study will assess surgical complications between cisgender, transgender, and nonbinary adults undergoing breast reductions. (English)

source label

INTRODUCTION (English)

subsection NLM category

2

2024

1 reference

The National Surgical Quality Improvement Program databases from 2015 to 2021 were used to identify TGD patients who underwent breast reduction (Current Procedural Terminology code: 19318) and cisgender patients who underwent this procedure for cosmesis or cancer prophylaxis. (English)

source label

METHODS (English)

subsection NLM category

3

2024

1 reference

Analysis of variance tests, chi-squared tests, unpaired t-tests, and regression models compared complications among cisgender, transgender, and nonbinary patients. (English)

source label

METHODS (English)

subsection NLM category

4

2024

1 reference

A total of 1222 patients met the inclusion criteria: 380 (31.1%) were cisgender, 769 (62.9%) were transgender, and 73 (6.0%) were nonbinary. (English)

source label

RESULTS (English)

subsection NLM category

5

2024

1 reference

The proportion of TGD patients grew significantly relative to cisgender patients over the study period (P < 0.001). (English)

source label

RESULTS (English)

subsection NLM category

6

2024

1 reference

The overall all-cause complication rate was 3.4%, with 4.2% of cisgender, 1.4% of nonbinary, and 3.1% of transgender patients experiencing surgical complications. (English)

source label

RESULTS (English)

subsection NLM category

7

2024

1 reference

After adjusting for confounding variables, no statistically significant difference was observed in all-cause complication rates between the cohorts. (English)

source label

RESULTS (English)

subsection NLM category

8

2024

1 reference

In the sample, 19 transgender patients (2.5%) underwent reoperation. (English)

source label

RESULTS (English)

subsection NLM category

9

2024

1 reference

Transgender patients had a lower likelihood of wound complications (odds ratio: 0.172; 95% confidence interval: 0.035-0.849; P = 0.031) compared to cisgender patients and nonbinary patients. (English)

source label

RESULTS (English)

subsection NLM category

10

2024

1 reference

None of the patients experienced a severe systemic complication. (English)

source label

RESULTS (English)

subsection NLM category

11

2024

1 reference

The findings emphasize the growing demand and safety of gender-affirming breast reductions. (English)

source label

CONCLUSIONS (English)

subsection NLM category

12

2024

1 reference

They underscore the importance of continued research and tailored approaches to delivering care to nonbinary and transgender patients, addressing their diverse needs and improving access to gender-affirming surgeries. (English)

source label

CONCLUSIONS (English)

subsection NLM category

13

2024